176 related articles for article (PubMed ID: 12774796)
1. [96-week treatment outcome confirms long term efficacy of tenofovir DF].
Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796
[No Abstract] [Full Text] [Related]
2. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
[No Abstract] [Full Text] [Related]
3. Tenofovir disoproxil fumarate.
Gallant JE; Deresinski S
Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
[TBL] [Abstract][Full Text] [Related]
4. [No comparison with NRTI. Tenofovir is robust against resistance trouble].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079
[No Abstract] [Full Text] [Related]
5. [First nucleotide analog on the market. New drug for the pretreated patient].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():84. PubMed ID: 12043094
[No Abstract] [Full Text] [Related]
6. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
Shere-Wolfe KD; Verley JR
Clin Infect Dis; 2002 Nov; 35(9):1137. PubMed ID: 12384851
[No Abstract] [Full Text] [Related]
7. New antiretroviral for HIV infection.
Am Fam Physician; 2002 Mar; 65(5):987. PubMed ID: 11898969
[No Abstract] [Full Text] [Related]
8. [First nucleotide analog against HIV. Lowers viral load also in drug resistance].
MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157
[No Abstract] [Full Text] [Related]
9. [Tenofovir--a new option for combination therapy].
Polk B
Med Monatsschr Pharm; 2002 Apr; 25(4):140-1. PubMed ID: 12017127
[No Abstract] [Full Text] [Related]
10. Effect of tenofovir on didanosine absorption in patients with HIV.
Pecora Fulco P; Kirian MA
Ann Pharmacother; 2003 Sep; 37(9):1325-8. PubMed ID: 12921517
[TBL] [Abstract][Full Text] [Related]
11. Viread gets FDA nod.
Rodriquez E
Posit Living; 2001 Dec-2002 Jan; 10(7):33. PubMed ID: 11808509
[No Abstract] [Full Text] [Related]
12. [Tenofovir (Viread)].
Sidahora; 2002; (1):20-1. PubMed ID: 12772661
[No Abstract] [Full Text] [Related]
13. Tenofovir: FDA hearing October 3, public comment deadlines September 26.
James JS
AIDS Treat News; 2001 Aug; (370):3-4. PubMed ID: 11570163
[No Abstract] [Full Text] [Related]
14. [First nucleotide analog with noteworthy safety profile. Tenofovir effective in all stages of the infection].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():62-4. PubMed ID: 15011594
[No Abstract] [Full Text] [Related]
15. 96-week CASTLE data show similar efficacy results.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
[No Abstract] [Full Text] [Related]
16. [Simply convincing. New fixed combination for HIV therapy].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():20-3. PubMed ID: 16385865
[No Abstract] [Full Text] [Related]
17. [Further indications for tenofovir].
Dtsch Med Wochenschr; 2003 Sep; 128(39):2037. PubMed ID: 14565207
[No Abstract] [Full Text] [Related]
18. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome.
Schaaf B; Aries SP; Kramme E; Steinhoff J; Dalhoff K
Clin Infect Dis; 2003 Aug; 37(3):e41-3. PubMed ID: 12884188
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir--long term results from first-line therapy.
TreatmentUpdate; 2003; 15(2):4-6. PubMed ID: 12693361
[No Abstract] [Full Text] [Related]
20. Tenofovir and didanosine: a dangerous liaison.
Waters L; Maitland D; Moyle GJ
AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
[No Abstract] [Full Text] [Related]
[Next] [New Search]
